Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2006;47:1183-1188
Published online before print April 24, 2006, doi: 10.1161/01.HYP.0000221429.94591.72
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/6/1183    most recent
01.HYP.0000221429.94591.72v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hattori, Y.
Right arrow Articles by Kasai, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hattori, Y.
Right arrow Articles by Kasai, K.
Related Collections
Right arrow Type 2 diabetes
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Cell signalling/signal transduction

(Hypertension. 2006;47:1183.)
© 2006 American Heart Association, Inc.


Original Articles

Metformin Inhibits Cytokine-Induced Nuclear Factor {kappa}B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells

Yoshiyuki Hattori; Kunihiro Suzuki; Sachiko Hattori; Kikuo Kasai

From the Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi, Japan.

Correspondence to Yoshiyuki Hattori, Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi 321-0293, Japan. E-mail yhattori{at}dokkyomed.ac.jp

AMP-activated protein kinase (AMPK) is tightly regulated by the cellular AMP:ATP ratio and plays a central role in regulation of energy homeostasis and metabolic stress. Metformin has been shown to activate AMPK. We hypothesized that metformin may prevent nuclear factor {kappa}B (NF-{kappa}B) activation in endothelial cells exposed to inflammatory cytokines. Metformin was observed to activate AMPK, as well as its downstream target, phosphoacetyl coenzyme A carboxylase, in human umbilical vein endothelial cells (HUVECs). Metformin also dose-dependently inhibited tumor necrosis factor (TNF)-{alpha}–induced NF-{kappa}B activation and TNF-{alpha}–induced I{kappa}B kinase activity. Furthermore, metformin attenuated the TNF-{alpha}–induced gene expression of various proinflammatory and cell adhesion molecules, such as vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1, in HUVECs. A pharmacological activator of AMPK, 5-amino-4-imidazole carboxamide riboside (AICAR), dose-dependently inhibited TNF-{alpha}- and interleukin-1ß–induced NF-{kappa}B reporter gene expression. AICAR also suppressed the TNF-{alpha}- and interleukin-1ß–induced gene expression of vascular cell adhesion molecule-1, E-selectin, intercellular adhesion molecule-1, and monocyte chemoattractant protein-1 in HUVECs. The small interfering RNA for AMPK{alpha}1 attenuated metformin or AICAR–induced inhibition of NF-{kappa}B activation by TNF-{alpha}, suggesting a possible role of AMPK in the regulation of cell inflammation. In light of these findings, we suggest that metformin attenuates the cytokine-induced expression of proinflammatory and adhesion molecule genes by inhibiting NF-{kappa}B activation via AMPK activation. Thus, it might be useful to target AMPK signaling in future efforts to prevent atherogenic and inflammatory vascular disease.


Key Words: endothelium • cell adhesion molecules • diabetes mellitus




This article has been cited by other articles:


Home page
Am. J. Respir. Crit. Care Med.Home page
J. W. Zmijewski, E. Lorne, X. Zhao, Y. Tsuruta, Y. Sha, G. Liu, G. P. Siegal, and E. Abraham
Mitochondrial Respiratory Complex I Regulates Neutrophil Activation and Severity of Lung Injury
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 168 - 179.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
S. S Lund, L. Tarnow, C. D A Stehouwer, C. G Schalkwijk, T. Teerlink, J. Gram, K. Winther, M. Frandsen, U. M Smidt, O. Pedersen, et al.
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
Eur. J. Endocrinol., May 1, 2008; 158(5): 631 - 641.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Qin, M. Ni, and G. W. De Vries
Implication of S-Adenosylhomocysteine Hydrolase in Inhibition of TNF-{alpha}- and IL-1{beta}-Induced Expression of Inflammatory Mediators by AICAR in RPE Cells
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1274 - 1281.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. S. Gaskin, K. Kamada, M. Yusof, and R. J. Korthuis
5'-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H326 - H332.
[Abstract] [Full Text] [PDF]